

# Orphan Drugs Market is estimated to be US\$ 869.6 billion by 2030 with a CAGR of 10.4% Over the forecast period - By PMI

*The report " Orphan Drugs Market, By Drug Type , By Top Selling Drugs , By Disease Type , By Phase , and By Region - Trends, Analysis and Forecast till 2030"*

COVINA, CALIFORNIA, UNITED STATES, March 16, 2023 /EINPresswire.com/ --

The [ORPHAN DRUGS MARKET](#) is estimated to be US\$ 869.6 million by 2030 with a CAGR of 10.4% during the forecast period. Orphan drugs are the pharmaceutical mediators which are developed to treat rare medical

conditions. Orphan drugs would not be able to earn profit because the orphan drugs are used to treat the rare diseases. It can only produce profit by the involvement of government assistant. Orphan drugs use to diagnoses and to prevent the diseases. Orphan drugs are not developed in industry, but it is generated for the public welfare.



“

Orphan drugs provide hope to those suffering from rare diseases, transforming what were once considered hopeless cases into opportunities for treatment and improved quality of life”  
*Prophecy Market Insights*

The report " Orphan Drugs Market, By Drug Type (Biological and Non- Biological), By Top Selling Drugs (Revlimid, Rituxan, Copaxone, Opdivo, Keytruda, Imbruvica, Avonex, Sensipar, Soliris, and Other Top Selling Drugs), By Disease Type (Oncology, Hematology, Neurology, Cardiovascular, and Other Disease Types), By Phase (Phase I, Phase II, Phase III, and Phase IV), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Trends, Analysis and Forecast till 2030"

## Key Highlights:

- In present scenario, there are several countries and organizations, which have defined "orphan" and "rare" diseases. The prevalence rate for each definition varies from organization to

organization, and country to country. While, several developed markets have specific definition for such diseases and treatments, there are however, many countries in the emerging markets, which lack the proper definitions and guidelines, along with lack of proper guidance from the medical community and concerned authorities toward the orphan diseases. This is among the major challenges and restraints for growth of orphan medication, across a large part of the world.

- In August 2019, Janssen and AbbVie received the European Commission (EC) approval of imbruvica (ibrutinib) for expanded use in two indications. The regulator has approved expanding the scope of the drug to include its use in combination with obinutuzumab in adults with previously untreated chronic lymphocytic leukemia (CLL), and for the treatment of adults with Waldenström's macroglobulinemia (WM) in combination with rituximab.

#### Analyst View:

In present scenario, there are several countries and organizations, which have defined “orphan” and “rare” diseases. The prevalence rate for each definition varies from organization to organization, and country to country. While, several developed markets have specific definition for such diseases and treatments, there are however, many countries in the emerging markets, which lack the proper definitions and guidelines, along with lack of proper guidance from the medical community and concerned authorities toward the orphan diseases. This is among the major challenges and restraints for growth of orphan medication, across a large part of the world.

#### Scope of the Report:

##### 1. Market Preview

>Executive Summary

>Key Findings—Global Outlook for Orphan Drugs Strategies

- Key Questions this Study will Answer
- Global Orphan Drugs Market, By Drug Type:

>Biological

>Non- Biological

Global Orphan Drugs Market, By Top Selling Drugs:

- Revlimid
- Rituxan
- Copaxone
- Opdivo
- Keytruda
- Imbruvica
- Avonex
- Sensipar
- Soliris
- Other Top Selling Drugs

## Global Orphan Drugs Market, By Disease Type:

- Oncology
- Hematology
- Neurology
- Cardiovascular
- Other Disease Types

## Global Orphan Drugs Market, By Phase Type:

- Phase I
- Phase II
- Phase III
- Phase IV

### >Opportunity Map Analysis

### >Executive Summary—3 Big Predictions

## 2. Market Dynamics, Regulations, and Trends Analysis

### >Market Dynamics

- Drivers
- Restraints
- Market Opportunities
- Market Trends
- DR Impact Analysis
- PEST Analysis
- Porter's Five Forces Analysis
- Opportunity Orbit
- Overview
- Market Value and Forecast (US\$ Mn), and Share Analysis (%), 2020 – 2030
- Y-o-Y Growth Analysis (%), 2020 – 2030
- Regional Trends
- Market Investment Feasibility Index
- Macroeconomic Factor Analysis

Download a Free Sample:

[https://www.prophecymarketinsights.com/market\\_insight/Insight/request-sample/3793](https://www.prophecymarketinsights.com/market_insight/Insight/request-sample/3793)

Key Market Insights from the report:

The Global Orphan Drugs Market is estimated to be US\$ 869.6 million by 2030 with a CAGR of 10.4% during the forecast period. The global orphan drugs market is segmented based on drug type, disease, disease type, phase, and region.

- On the basis of drug type, the global orphan drugs market is segmented into biological and non- biological.
- On the basis of top selling drugs, the target market is segmented into revlimid, rituxan, copaxone, opdivo, keytruda, imbruvica, avonex, sensipar,

soliris, and other top selling drugs.

- ased on disease type, the global market is classified into oncology, hematology, neurology, cardiovascular, and other disease types.
- On the basis of phase segment, the target market divided into phase I, phase II, phase III, and phase IV.
- Based on region the global orphan drugs market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The global market in North America region is seen to have a matured growth since this market correlates with the increasing growth rate of orphan disease.

Competitive Landscape:

- AbbVie Inc
- Celgene Corporation
- Biogen
- Teva Pharmaceutical Industries
- F. Hoffmann-La Roche AG
- Bristol-Myers Squibb Company
- Alexion Pharmaceuticals
- Amgen
- Merck & Co. Inc.

Jazz Pharmaceuticals Prominent players operating in the target market are focusing on the strategic partnerships as well as launching of the drug types in order to gain competitive edge in the target market.

The market provides detailed information regarding the industrial base, productivity, strengths, manufacturers, and recent trends which will help companies enlarge the businesses and promote financial growth. Furthermore, the report exhibits dynamic factors including segments, sub-segments, regional marketplaces, competition, dominant key players, and market forecasts. In addition, the market includes recent collaborations, mergers, acquisitions, and partnerships along with regulatory frameworks across different regions impacting the market trajectory. Recent technological advances and innovations influencing the global market are included in the report.

Some Important Points Answered in this Market Report Are Given Below:

- Explains an overview of the product portfolio, including product development, planning, and positioning
- Explains details about key operational strategies with a focus on R&D strategies, corporate structure, localization strategies, production capabilities, and financial performance of various companies.
- Detailed analysis of the market revenue over the forecasted period.

- Examining various outlooks of the market with the help of Porter's five forces analysis, PEST & SWOT Analysis.
- Study on the segments that are anticipated to dominate the market.
- Study on the regional analysis that is expected to register the highest growth over the forecast period

Other related Reports:

[Wheelchair Lift Market](#): By Automotive Lift (Occupied lifts, and Unoccupied lifts), By Building Lift (Residential, and Commercial), By Power Type (Electric, and Hydraulic), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Trends, Analysis and Forecast till 2030

[Hydroxychloroquine Market](#): By Disease Type (Coronavirus Disease (COVID-19), Malaria, Q Fever, Rheumatoid Arthritis, Lupus Erythematosus, Porphyria Cutanea Tarda (PCT), and Other Disease Types), By Distribution Channel (Specialty Drug Store, Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Trends, Analysis, and Forecast till 2029

Shweta Raskar

Prophecy Market Insights

+1 860-531-2701

[email us here](#)

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

[YouTube](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/622512819>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2023 Newsmatics Inc. All Right Reserved.